COMPASS Pathways plc (CMPS) reported Q2 EPS of ($0.50), $0.11 better than the analyst estimate of ($0.61).
By David Wagner and Yassine MaroufiInvesting.com - Many growth investors are looking for the latest high-potential investment themes so as to buy the right stocks ahead of most...
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.